Video Summary - Biggest Green Day of the Challenge!

Finance-focused summary (Day 20 of small account challenge)

Goal/Setup: Grow a $2,000 account using Charles Schwab (broker). Money is being donated to children’s hospitals; trading performance directly funds donations.
Day’s trading results:
- 3 trades total: 2 winners, 1 loser → 66% accuracy for the morning (below the challenge’s usual pace).
- The loser was stopped out quickly, keeping the loss “small and manageable,” while the winners were larger.
Cumulative performance:
- 45 trades over 20 days (avg ~2.4–2.5 trades/day).
- Account is up over 1,300% vs. the $2,000 start.
- Overall record (as stated): 48 winners / 37 winners / 11 losers (some numbers appear inconsistent in subtitles), with 77% accuracy.
- Average winners: $560.

Trade only if there is a valid setup (avoid trading to “make back” a loss).
Risk sizing rule: size risk based on the difference between entry and max loss.
Profit target rule: aim for a profit target ≥ 2x the amount risked (2:1 reward:risk).
Stock selection: focus on “8 quality setups” that meet “five pillars” of stock selection (framed as a reason behind ~77% accuracy during the challenge).

ERNA (biotech)
VIVS (biotech)
UBXG (mentioned as a comparison risk—referenced as causing trouble in a prior loss)

Catalyst: “Breaking news” biotech-related squeeze.
Price / Move:
- Scanner alert at 9:09
- Rapid squeeze +54%, later described as up to ~55% and +75% intraday.
- Key levels discussed: 10.62, with higher spikes on lower timeframes up to about 11.50, 11.75, 12.50.
Execution logic:
- Waited for break of 10; noted it wasn’t “super clean” (popped/dipped/chopped).
- Entered on early momentum; took profit on the straddle around 10.
- Avoided the later part of the move due to concern about a “weird/choppy” pattern.
Risk / event caution (explicit):
- Compared behavior to UBXG, where he previously lost about $6,000 in his “big account” due to repeated stop-outs after a choppy recovery.
P&L: +$873.52
Order sizing (approx., from subtitle interpretation):
- Subtitles imply two orders of ~2,000 shares (and mention “~20 cents a share”)
- Total implied size: ~4,000 shares for the trade.

Catalyst: Received a $5 million payment from Eli Lilly.
Guidance: Expects revenue growth of 500% in the 2027 fiscal year.
Price / Move:
- Scanner hit around $1.25, up about 49% initially.
- Notes 200-day moving average near $1.80.
- Price moved up to roughly $1.20–$1.60 levels before it ultimately broke ~$1.80.
- Entry/target levels discussed:
  - Break of $2
  - Spike sequence: $2.20 → $2.40 → $2.50 → $2.70
  - Then up to about $3.00 (peak)
- Later attempt to re-enter for continuation toward $4, but he was stopped.
Execution notes:
- Entered on the break of $2 after it cleared the $1.80 (200 MA) area.
- Took profit near $3, then added back on a pullback for continuation.
- Continuation failed; he stopped out.
Order sizing (approx.):
- Subtitles indicate about 4,000 shares total across entries/adds (partial fills mentioned).
- Commentary suggests he could have afforded up to 10,000 shares, but that would have been too risky due to single-trade concentration risk.

The subtitles primarily detail two tickers (ERNA and VIVS), but the summary states 3 trades total with 1 loser.
The VIVS narrative includes a stop-out, which likely corresponds to the third trade/loss, though subtitles do not clearly label it as “third.”

Do not spiral after a loss: after the stop-out, he “took his foot off the gas.”
Don’t trade just to recover P&L: markets don’t care about losses.
Avoid increasing position size to compensate for a loss.
Trade only with a valid setup, using defined risk and a ≥2:1 reward:risk structure.
Be cautious with choppy “fake-out” patterns: highlighted via comparison to a prior UBXG loss.

Ross (speaker; references his “t-shirt” and mentions “I’ll see you guys back…”)
Charles Schwab (broker used in the challenge)
Eli Lilly (company mentioned as the VIVS catalyst; not as a presenter)
Warrior Trading (promoted via a 2-week trial link)